Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects

DNA and Cell Biology

Volumn 31, Issue 4, 2012, Pages 504-510

  Metzger, Ingrid F ^a   Luizon, Marcelo R ^a   Lacchini, Riccardo ^a   Tanus Santos, Jose Eduardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; METALLOPROTEINASE;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; COMPUTER PROGRAM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

AFRICAN CONTINENTAL ANCESTRY GROUP; BAYES THEOREM; BRAZIL; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MATRIX METALLOPROTEINASE 9; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84859785259     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1388     Document Type: Article

References (37)

1. Allan, J.A., Docherty, A.J., Barker, P.J., Huskisson, N.S., Reynolds, J.J., and Murphy, G. (1995). Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 309(Pt 1), 299-306.
2. Bahrami, H., Kronmal, R., Bluemke, D.A., Olson, J., Shea, S., Liu, K., Burke, G.L., and Lima, J.A. (2008). Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 168, 2138-2145.
3. Belo, V.A., Souza-Costa, D.C., Lana, C.M., Caputo, F.L., Marcaccini, A.M., Gerlach, R.F., Bastos, M.G., and Tanus-Santos, J.E. (2009). Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42, 984-990.
4. Bibbins-Domingo, K., Pletcher, M.J., Lin, F., Vittinghoff, E., Gardin, J.M., Arynchyn, A., Lewis, C.E., Williams, O.D., and Hulley, S.B. (2009). Racial differences in incident heart failure among young adults. N Engl J Med 360, 1179-1190.
5. Blankenberg, S., Rupprecht, H.J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F., and Tiret, L. (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107, 1579-1585.
6. Carroll, J.F., Fulda, K.G., Chiapa, A.L., Rodriquez, M., Phelps, D.R., Cardarelli, K.M., Vishwanatha, J.K., and Cardarelli, R. (2009). Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity 17, 1420-1427.
7. Castro, M.M., Rizzi, E., Figueiredo-Lopes, L., Fernandes, K., Bendhack, L.M., Pitol, D.L., Gerlach, R.F., and Tanus-Santos, J.E. (2008). Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198, 320-331.
8. Castro, M.M., Rizzi, E., Prado, C.M., Rossi, M.A., Tanus-Santos, J.E., and Gerlach, R.F. (2010). Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 29, 194-201.
9. Demacq, C., de Souza, A.P., Machado, A.A., Gerlach, R.F., and Tanus-Santos, J.E. (2006). Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365, 183-187.
10. Demacq, C., Metzger, I.F., Gerlach, R.F., and Tanus-Santos, J.E. (2008a). Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin Chim Acta 394, 72-76.
11. Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., Gerlach, R.F., Machado, A.A., and Tanus-Santos, J.E. (2009). A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 9, 265-273.
12. Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., Gerlach, R.F., Silva, W.A., Jr., and Tanus-Santos, J.E. (2008b). Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46, 57-63.
13. Fontana, V., Silva, P.S., Belo, V.A., Antonio, R.C., Ceron, C.S., Biagi, C., Gerlach, R.F., and Tanus-Santos, J.E. (2011). Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 109, 130-137.
14. Galis, Z.S., and Khatri, J.J. (2002). Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90, 251-262.
15. Garvin, P., Nilsson, L., Carstensen, J., Jonasson, L., and Kristenson, M. (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 3, e1774.
16. Gerlach, R.F., Demacq, C., Jung, K., and Tanus-Santos, J.E. (2007). Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40, 119-123.
17. Gerlach, R.F., Uzuelli, J.A., Souza-Tarla, C.D., and Tanus-Santos, J.E. (2005). Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344, 147-149.
18. Goncalves, F.M., Jacob-Ferreira, A.L., Gomes, V.A., Casella-Filho, A., Chagas, A.C., Marcaccini, A.M., Gerlach, R.F., and Tanus-Santos, J.E. (2009). Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403, 173-177.
19. Hozawa, A., Folsom, A.R., Sharrett, A.R., and Chambless, L.E. (2007). Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects- Atherosclerosis Risk in Communities Study. Arch Intern Med 167, 573-579.
20. Jacob-Ferreira, A.L., Passos, C.J., Gerlach, R.F., Barbosa, F., Jr., and Tanus-Santos, J.E. (2010). A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury. Sci Total Environ 408, 4085-4092.
21. Jacob-Ferreira, A.L., Passos, C.J., Jordao, A.A., Fillion, M., Mergler, D., Lemire, M., Gerlach, R.F., Barbosa, F., Jr., and Tanus-Santos, J.E. (2009). Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities. Basic Clin Pharmacol Toxicol 105, 281-88.
22. Lacchini, R., Jacob-Ferreira, A.L., Luizon, M.R., Coeli, F.B., Izidoro-Toledo, T.C., Gasparini, S., Ferreira-Sae, M.C., Schreiber, R., Nadruz, W., Jr., and Tanus-Santos, J.E. (2010a). Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 411, 1940-1944.
23. Lacchini, R., Metzger, I.F., Luizon, M., Ishizawa, M., and Tanus-Santos, J.E. (2010b). Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 29, 649-655.
24. Martinez, M.L., Rizzi, E., Castro, M.M., Fernandes, K., Bendhack, L.M., Gerlach, R.F., and Tanus-Santos, J.E. (2008). Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 599, 110-116.
25. Mensah, G.A., Mokdad, A.H., Ford, E.S., Greenlund, K.J., and Croft, J.B. (2005). State of disparities in cardiovascular health in the United States. Circulation 111, 1233-1241.
26. Metzger, I.F., Ishizawa, M.H., Rios-Santos, F., Carvalho, W.A., and Tanus-Santos, J.E. (2011). Endothelial nitric oxide synthase gene haplotypes affect nitrite levels in black subjects. Pharmacogenomics J. doi:10.1038/tpj.2010.52 (Epub ahead of print).
27. Metzger, I.F., Sertorio, J.T., and Tanus-Santos, J.E. (2006). Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol 188, 123-127.
28. Metzger, I.F., Sertorio, J.T., and Tanus-Santos, J.E. (2007). Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43, 987-992.
29. Metzger, I.F., Souza-Costa, D.C., Marroni, A.S., Nagassaki, S., Desta, Z., Flockhart, D.A., and Tanus-Santos, J.E. (2005). Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15, 565-570.
30. Price, S.J., Greaves, D.R., and Watkins, H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276, 7549-7558.
31. Rizzi, E., Castro, M.M., Prado, C.M., Silva, C.A., Fazan, R., Jr., Rossi, M.A., Tanus-Santos, J.E., and Gerlach, R.F. (2010). Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 16, 599-608.
32. Schaid, D.J., Rowland, C.M., Tines, D.E., Jacobson, R.M., and Poland, G.A. (2002). Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70, 425-434.
33. Shimajiri, S., Arima, N., Tanimoto, A., Murata, Y., Hamada, T., Wang, K.Y., and Sasaguri, Y. (1999). Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 455, 70-74.
34. Stephens, M., Smith, N.J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68, 978-989.
35. Sundstrom, J., and Vasan, R.S. (2006). Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 17, 45-53.
36. Timms, P.M., Mannan, N., Hitman, G.A., Noonan, K., Mills, P.G., Syndercombe-Court, D., Aganna, E., Price, C.P., and Boucher, B.J. (2002). Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95, 787-796.
37. Zhang, B., Ye, S., Herrmann, S.M., Eriksson, P., de Maat, M., Evans, A., Arveiler, D., Luc, G., Cambien, F., Hamsten, A., Watkins, H., and Henney, A.M. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99, 1788-1794.